SCHEMBL1385653

SCHEMBL1385653

Cc1c(C(=O)O)oc2cc(Cl)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 1.00
KDM4E B2RXH2 6/20 0.63
ALDH1A1 P00352 4/20 0.63
GPR35 Q9HC97 1/20 0.58
TTR P02766 2/20 0.53
MEN1 O00255 1/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 1/20 0.51
KCNH2 Q12809 1/20 0.49
HPGD P15428 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
GAA P10253 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
AHR P35869 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HSD17B3 P37058 1/20 0.43
PKM P14618 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6329907 0.89 MCL1 (0.80) MCL1KDM4EALDH1A1GPR35TTR
SCHEMBL3498475 0.88 MCL1 (0.78) MCL1KDM4EALDH1A1GPR35TTR
SCHEMBL4615856 0.87 MCL1 (1.00) MCL1KDM4EALDH1A1GPR35TTR
SCHEMBL4655120 0.83 MCL1 (0.71) MCL1KDM4EALDH1A1GPR35MEN1
SCHEMBL11095441 0.83 MCL1 (0.70) MCL1KDM4EALDH1A1TTRKMT2A
SCHEMBL4738325 0.81 MCL1 (0.69) MCL1KDM4EALDH1A1GPR35TTR
SCHEMBL20893367 0.80 MCL1 (0.67) MCL1KDM4EALDH1A1MEN1KMT2A
SCHEMBL4763051 0.80 MCL1 (0.67) MCL1KDM4EALDH1A1GPR35HPGD
SCHEMBL16684635 0.80 MCL1 (0.67) MCL1KDM4EALDH1A1GPR35KCNH2
SCHEMBL10652526 0.80 MCL1 (0.67) MCL1KDM4EALDH1A1GPR35MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4829449-B2 2011-12-07 JP claimed
JP-2003508353-A 2003-03-04 JP claimed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 EP claimed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 WO claimed
CN-113416216-B High-activity Pt complex and preparation method and application thereof 江苏南创化学与生命健康研究院有限公司 2021-10-29 CN disclosed
CN-113416216-B High-activity Pt complex and preparation method and application thereof 江苏南创化学与生命健康研究院有限公司 2021-10-29 CN disclosed
CN-113416216-A High-activity Pt complex and preparation method and application thereof 江苏南创化学与生命健康研究院有限公司 2021-09-21 CN disclosed
CN-113416216-A High-activity Pt complex and preparation method and application thereof 江苏南创化学与生命健康研究院有限公司 2021-09-21 CN disclosed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US disclosed
CN-1420882-A Substd. oxoazaheterocyclyl compounds AVENTIS PHARM PROD INC (US) 2003-05-28 CN disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 EP disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 MCL1 2759/4885KDM4E 2943/4885ALDH1A1 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.